193 related articles for article (PubMed ID: 30723937)
1. Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients.
Barra ME; Berger K; Tesoro EP; Brophy GM
Pharmacotherapy; 2019 Mar; 39(3):317-334. PubMed ID: 30723937
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience.
Hanel RA; Taussky P; Dixon T; Miller DA; Sapin M; Nordeen JD; Tawk RG; Navarro R; Johns G; Freeman WD
J Neurointerv Surg; 2014 May; 6(4):320-2. PubMed ID: 23771209
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
Aguilar-Salinas P; Agnoletto GJ; Brasiliense LBC; Santos R; Granja MF; Gonsales D; Aghaebrahim A; Sauvageau E; Hanel RA
J Neurointerv Surg; 2019 Apr; 11(4):347-351. PubMed ID: 30552167
[TBL] [Abstract][Full Text] [Related]
6. Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity.
Ather A; Beavers CJ
Curr Vasc Pharmacol; 2019; 17(2):127-132. PubMed ID: 30058492
[TBL] [Abstract][Full Text] [Related]
7. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention.
Linfante I; Ravipati K; Starosciak AK; Reyes D; Dabus G
J Neurointerv Surg; 2021 Jan; 13(1):30-32. PubMed ID: 32414891
[TBL] [Abstract][Full Text] [Related]
8. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
[TBL] [Abstract][Full Text] [Related]
9. Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Jones GM; Twilla JD; Hoit DA; Arthur AS
J Neurointerv Surg; 2013 Sep; 5(5):e38. PubMed ID: 23223398
[TBL] [Abstract][Full Text] [Related]
10. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
12. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
[TBL] [Abstract][Full Text] [Related]
13. Management of antiplatelet therapy in patients undergoing neuroendovascular procedures.
Kim KS; Fraser JF; Grupke S; Cook AM
J Neurosurg; 2018 Oct; 129(4):890-905. PubMed ID: 29192856
[TBL] [Abstract][Full Text] [Related]
14. P2Y
Kupka D; Sibbing D
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):303-315. PubMed ID: 29338536
[TBL] [Abstract][Full Text] [Related]
15. Switching P2Y
Rollini F; Franchi F; Angiolillo DJ
Interv Cardiol Clin; 2017 Jan; 6(1):67-89. PubMed ID: 27886824
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Shah R; Rashid A; Hwang I; Fan TM; Khouzam RN; Reed GL
Am J Cardiol; 2017 Jun; 119(11):1723-1728. PubMed ID: 28385176
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
18. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
19. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Ticagrelor on Platelet Reactivity in Patients with Clopidogrel Resistance Undergoing Neuroendovascular Procedures.
Qureshi AI; Jahngir MU; Qualls K; Akinci Y; Lobanova I; Liaqat J; Gao X; Akhtar IN; Kraus J; Uzun G; French B; Siddiq F; Ramiro Gomez C
J Neuroimaging; 2020 May; 30(3):327-334. PubMed ID: 32301181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
